About Cytonics
Cytonics is a Healthcare company based in Jupiter (United States) founded in 2006 by Gaetano Scuderi. Diagnostics and therapeutics for osteoarthritis are developed. Cytonics has raised $3.33 million across 8 funding rounds from investors including HHS and NIH SBIR/STTR. The company has 8 employees. Its chief executive, as recorded, is Joey Bose. Cytonics offers products and services including APIC™ System, FACT™ Diagnostic, and CYT-108. Its focus areas include Life Sciences, Immunology, In Vitro Diagnostic Tests and Rheumatoid Arthritis. Its legal entity is Cytonics Corporation. Its competitors include PierianDx, Circular Genomics and Ignyta; 3 of its 3 listed competitors have raised funding.
Company details
Cytonics was founded in 2006 in Jupiter, United States, within the biotechnology sector. Focus is placed on developing diagnostics and therapeutics for osteoarthritis. The flagship product, the Fibronectin-Aggrecan Complex Test (FACT), is utilized to detect cartilage damage from patients joint fluid samples. Operations center on advancing treatments and early detection methods for joint-related conditions.
- Headquarters Jupiter, United States
- Employees 8
- Founders Gaetano Scuderi
- SectorsHealthcare
- Website cytonics.com
- Social LinkedIn X Facebook Instagram
- Legal Name Cytonics Corporation
- Annual Revenue$417.5 K (USD)3as on Dec 31, 2023
- Net Profit-$2.84 M (USD)-48as on Dec 31, 2023
- Total Equity Funding$3.33M (USD)
in 8 rounds
- Latest Funding Round$25K (USD), Seed
Jun 2019
- InvestorsHHS
& 1 more
- Employee Count8
Products & Services of Cytonics
Cytonics offers a comprehensive portfolio of products and services, including APIC™ System, FACT™ Diagnostic, and CYT-108.
Autologous treatment using A2M to reduce osteoarthritis pain and inflammation
Test that detects cartilage damage in joint fluid for patient diagnosis
Recombinant A2M therapy aimed at improving cartilage protection in osteoarthritis
Funding Insights of Cytonics
Cytonics has successfully raised a total of $3.33M across 8 strategic funding rounds. The most recent funding activity was a Seed round of $25 thousand completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.33M
- Total Rounds 8
- Last Round Seed — $25,000
- First Round $2.3M
(May 2009)
- Investors Count 2
All 8 funding rounds of Cytonics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $25,000 | Seed | – | – | – |
| Nov 2012 | $1.6M | Grant | – | – | |
| May 2011 | $1.6M | Grant | – | – | |
| Apr 2011 | $1.6M | Grant | – | – | |
| Mar 2011 | $1M | Seed | – | – | – |
| Mar 2010 | $192,300 | Grant | – | – | |
| Feb 2010 | $192,300 | Grant | – | – | |
| May 2009 | $2.3M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Cytonics
Cytonics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sbir.nih.gov | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Cytonics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cytonics
13 people are tracked at Cytonics (3 in leadership, 10 in board & advisors); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Gaetano Scuderi | Founder & President | Leadership |
Joey Bose | CEO | Leadership |
Lewis Hanna | Chief Scientific Officer | Leadership |
David C. Yeomans | Scientific Advisor | Board & advisors |
Wayne Olan | Medical Advisor | Board & advisors |
Vanessa Gabrovsky Cuellar | Scientific Advisor | Board & advisors |
Joseph Buckwalter | Medical Advisor | Board & advisors |
Martin Angst | Medical Advisor | Board & advisors |
Geoff Abrams | Medical Advisor | Board & advisors |
Gordon Ramseier | Independent Board Member | Board & advisors |
Thomas San Giovanni | Medical Advisor | Board & advisors |
Jason M. Cuellar | Scientific Advisor | Board & advisors |
Tracey Goeken | Board Member | Board & advisors |
Complete people profiles for Cytonics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cytonics
3 dated milestones of Cytonics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Cytonics is founded.
- Funding First funding round of $2.3M.
- Funding Latest funding round, Seed, of $25K.
Competitors of Cytonics
Cytonics has 3 listed competitors in our database, 3 of them funded. They include PierianDx, Circular Genomics and Ignyta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pieriandx.com | 2014 | Saint Louis, United States | $69.35M | 188 | Genetic tests for individualized disease diagnosis are provided. | |
| circulargenomics.com | 2021 | Albuquerque, United States | $13.99M | 1 | RNA-based diagnostics and therapeutics for depression are developed and provided. | |
| ignyta.com | 2011 | San Diego, United States | $96.87M | 30 | Personalized medicine is developed for cancer and autoimmune diseases. |
Detailed competitors of Cytonics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cytonics
The website of Cytonics (cytonics.com) receives about 2K visits a month.
- Monthly visits2K
▼ 29.4% vs previous month
Websites whose visitors overlap most with Cytonics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
rheumatologycarehouston.com | rheumatologycarehouston.com | 100% | #4,132,921 | – | |
physioflexpro.com | physioflexpro.com | 81% | #2,674,937 | – |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Cytonics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cytonics
Complete news archive for Cytonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cytonics
Cytonics was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Cytonics is headquartered in Jupiter, United States. It is registered at Jupiter, Florida, United States.
Joey Bose is the CEO of Cytonics, as recorded in our data.
Cytonics is a funded company, having raised a total of $3.33M across 8 funding rounds to date. The company's 1st funding round was a Seed of $2.3M, raised on May 2009.
Cytonics has 8 employees.
Annual revenue of Cytonics is $417.5K as on Dec 31, 2023.
Cytonics was founded in 2006 in Jupiter, United States, within the biotechnology sector. Focus is placed on developing diagnostics and therapeutics for osteoarthritis. The flagship product, the Fibronectin-Aggrecan Complex Test (FACT), is utilized to detect cartilage damage from patients joint fluid samples. Operations center on advancing treatments and early detection methods for joint-related conditions.
Cytonics's top competitors include Circular Genomics, PierianDx and Ignyta.
Cytonics offers APIC™ System, FACT™ Diagnostic, and CYT-108.
Cytonics has 2 investors. Key investors include HHS, and NIH SBIR/STTR.
Cytonics operates through Cytonics Corporation.